Publication date: Jun 17, 2025
Therapeutic antibodies with lambda light chains (λ-Abs) are underrepresented compared to kappa light chains (_705-Abs). Here, we evaluated two SARS-CoV-2-specific monoclonal antibodies (mAbs) that exhibit high (P5C3) and low (H4) antigen binding as _705 and λ variants. mAbs expressed in glycoengineered Nicotiana benthamiana did not show differences in expression levels, glycosylation, and antigen binding, while _705-Abs exhibited slightly increased thermodynamic stability over λ-Abs. SARS-CoV-2 neutralization and IgG-FcγR immune complex studies revealed increased activities of H4 IgG1_705 compared to H4 IgG1λ, with no differences observed between P5C3 variants. Our results indicate that constant light chain variability and Ab specificity contribute to Ab features, a fact that should be considered in engineering therapeutics.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Antibody | Fcγ-receptor binding |
| H4 | monoclonal antibodies |
| Light | SARS-CoV-2 |
| Thermodynamic | stability |
| Underrepresented | virus neutralization |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | facility |
| drug | DRUGBANK | 2′-fluoro-5-ethylarabinosyluracil |
| disease | IDO | production |
| drug | DRUGBANK | Spinosad |
| disease | MESH | COVID 19 pandemic |
| drug | DRUGBANK | Aspartame |
| drug | DRUGBANK | Xylose |
| drug | DRUGBANK | Magnesium sulfate |
| drug | DRUGBANK | Nitrogen |
| drug | DRUGBANK | Tromethamine |
| drug | DRUGBANK | Edetic Acid |
| drug | DRUGBANK | Ascorbic acid |
| drug | DRUGBANK | Potassium Chloride |
| drug | DRUGBANK | Glycine |
| drug | DRUGBANK | Sodium lauryl sulfate |
| drug | DRUGBANK | Flunarizine |
| drug | DRUGBANK | Trypsin |
| disease | IDO | assay |
| disease | MESH | infection |
| drug | DRUGBANK | Carboxymethylcellulose |
| drug | DRUGBANK | Formaldehyde |
| drug | DRUGBANK | Biotin |
| drug | DRUGBANK | Amino acids |
| disease | IDO | blood |
| drug | DRUGBANK | Methylergometrine |
| disease | IDO | protein |
| disease | IDO | site |
| disease | IDO | cell |
| disease | IDO | process |
| drug | DRUGBANK | Coenzyme M |
| drug | DRUGBANK | Efavirenz |
| disease | MESH | viral infections |
| drug | DRUGBANK | Troleandomycin |
| disease | IDO | host |
| drug | DRUGBANK | Diethylstilbestrol |